JP6001560B2 - Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド - Google Patents
Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド Download PDFInfo
- Publication number
- JP6001560B2 JP6001560B2 JP2013551362A JP2013551362A JP6001560B2 JP 6001560 B2 JP6001560 B2 JP 6001560B2 JP 2013551362 A JP2013551362 A JP 2013551362A JP 2013551362 A JP2013551362 A JP 2013551362A JP 6001560 B2 JP6001560 B2 JP 6001560B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- cyclopenta
- pentamethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](C1)([C@@]1C1)C(C)(C)[C@](C)(*)C1C1CC1 Chemical compound C[C@](C1)([C@@]1C1)C(C)(C)[C@](C)(*)C1C1CC1 0.000 description 17
- BYGNXQVPFCTQRQ-UHFFFAOYSA-N CNCCS(=O)=O Chemical compound CNCCS(=O)=O BYGNXQVPFCTQRQ-UHFFFAOYSA-N 0.000 description 2
- QWVLBBPXSQJARZ-RTLCBTMGSA-N CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(O)=O)=CC2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(O)=O)=CC2)CC1)=O QWVLBBPXSQJARZ-RTLCBTMGSA-N 0.000 description 1
- YGIMWQYOELXDTN-XPGNLXOLSA-N CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(OC)=O)=CC2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(OC)=O)=CC2)CC1)=O YGIMWQYOELXDTN-XPGNLXOLSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N CC(C)(C)OC(N1CCNCC1)=O Chemical compound CC(C)(C)OC(N1CCNCC1)=O CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- FQBSNYKEVQRTGJ-CJBPRDETSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCN(CC1)CCS1(=O)=O)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCN(CC1)CCS1(=O)=O)=O FQBSNYKEVQRTGJ-CJBPRDETSA-N 0.000 description 1
- JJBDPUIADXRHAM-SJWZJFCOSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C(C(CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C(C(CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O JJBDPUIADXRHAM-SJWZJFCOSA-N 0.000 description 1
- XDMUFNNPLXHNKA-UOBQYIRLSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O XDMUFNNPLXHNKA-UOBQYIRLSA-N 0.000 description 1
- IHYUWIZUYGJJIZ-IWGVNVMRSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CCC1)C1=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CCC1)C1=O IHYUWIZUYGJJIZ-IWGVNVMRSA-N 0.000 description 1
- YWAOPMYURACBJP-OOCSKDHWSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21N Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21N YWAOPMYURACBJP-OOCSKDHWSA-N 0.000 description 1
- AISLWPVTCPKMJI-MMSIMHLJSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CBr)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CBr)=O AISLWPVTCPKMJI-MMSIMHLJSA-N 0.000 description 1
- ZHNKUNSJZUCWBD-FKDSFBNWSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O ZHNKUNSJZUCWBD-FKDSFBNWSA-N 0.000 description 1
- JFNBJKABAZREHW-VYVBUBKVSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O JFNBJKABAZREHW-VYVBUBKVSA-N 0.000 description 1
- JHXCYXAOEJTMFI-NNWDMIHZSA-N CC(C)(C1CC2)C(c3ccc(C(O)=O)c(F)c3)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C(CCC1)C21NCCN(CCC1)C1=O Chemical compound CC(C)(C1CC2)C(c3ccc(C(O)=O)c(F)c3)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C(CCC1)C21NCCN(CCC1)C1=O JHXCYXAOEJTMFI-NNWDMIHZSA-N 0.000 description 1
- GUGJFDYYKQWAFY-RLSSSYFUSA-N CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O GUGJFDYYKQWAFY-RLSSSYFUSA-N 0.000 description 1
- OYAHCYCTSFKNPU-FSVNXHQXSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H](C(CC1)C(C)=C)[C@@]21NC(CN(C)C(CC1)CS1(=O)=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H](C(CC1)C(C)=C)[C@@]21NC(CN(C)C(CC1)CS1(=O)=O)=O OYAHCYCTSFKNPU-FSVNXHQXSA-N 0.000 description 1
- OASIVQNLIIJMLP-QSIOBENTSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CCCN(C)C)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CCCN(C)C)=O OASIVQNLIIJMLP-QSIOBENTSA-N 0.000 description 1
- UQQINAJJQRKTJI-ZVJJJHPOSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(c1cc(Cl)ccc1CO1)C1=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(c1cc(Cl)ccc1CO1)C1=O)=O UQQINAJJQRKTJI-ZVJJJHPOSA-N 0.000 description 1
- GLZZVNCQMVOTRR-QSIOBENTSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN1CCOCC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN1CCOCC1)=O GLZZVNCQMVOTRR-QSIOBENTSA-N 0.000 description 1
- ABHNQIOWBISBEJ-DJZGOYIYSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(C[n]1c2ccccc2cc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(C[n]1c2ccccc2cc1)=O ABHNQIOWBISBEJ-DJZGOYIYSA-N 0.000 description 1
- ZPRJWSXBZDMOHA-PQBBHEMQSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN(C)C)CCO)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN(C)C)CCO)=O ZPRJWSXBZDMOHA-PQBBHEMQSA-N 0.000 description 1
- XXYDPDHEVQQOOZ-NFEAHYNFSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN1)CC1=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN1)CC1=O)=O XXYDPDHEVQQOOZ-NFEAHYNFSA-N 0.000 description 1
- RQRKMYCFISPBBY-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCN(C)CC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCN(C)CC1)=O RQRKMYCFISPBBY-WECSNRJHSA-N 0.000 description 1
- ZHZLXPYNSCWUGX-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCNCCC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCNCCC1)=O ZHZLXPYNSCWUGX-WECSNRJHSA-N 0.000 description 1
- AQCBMRIJWMNIGN-WYJOASSBSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NC1(CN2CCCCC2)CC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NC1(CN2CCCCC2)CC1)=O AQCBMRIJWMNIGN-WYJOASSBSA-N 0.000 description 1
- VGKROGOCYRVUEN-PQBBHEMQSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCC[n]1cncc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCC[n]1cncc1)=O VGKROGOCYRVUEN-PQBBHEMQSA-N 0.000 description 1
- QASSSLZQIDWHOB-LYJCWSOSSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCN(C)C)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCN(C)C)=O QASSSLZQIDWHOB-LYJCWSOSSA-N 0.000 description 1
- VJCOSSYTGQQZIU-LTJMNYHZSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCCN(CC1)CCS1(=O)=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCCN(CC1)CCS1(=O)=O)=O VJCOSSYTGQQZIU-LTJMNYHZSA-N 0.000 description 1
- NHIGHKDCJXTDSV-NNOKGMCDSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCN1C(C)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCN1C(C)=O NHIGHKDCJXTDSV-NNOKGMCDSA-N 0.000 description 1
- FFSBSDYATDEFDZ-FJMUSEAASA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN1CCN(C)CC1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN1CCN(C)CC1 FFSBSDYATDEFDZ-FJMUSEAASA-N 0.000 description 1
- KGCBDIJYPDRXJJ-NNOKGMCDSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ccccc1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ccccc1 KGCBDIJYPDRXJJ-NNOKGMCDSA-N 0.000 description 1
- AWRIISJQIWZBKG-RPSIQIFRSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1nc(SC)ccn1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1nc(SC)ccn1 AWRIISJQIWZBKG-RPSIQIFRSA-N 0.000 description 1
- LLMRAPIERIHZOY-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[n]1C Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[n]1C LLMRAPIERIHZOY-WECSNRJHSA-N 0.000 description 1
- CQICLCMCGHJSQL-LYJCWSOSSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[s]1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[s]1 CQICLCMCGHJSQL-LYJCWSOSSA-N 0.000 description 1
- CWKKIZCMKSXJOQ-LCYMYPGXSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21N=C=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21N=C=O CWKKIZCMKSXJOQ-LCYMYPGXSA-N 0.000 description 1
- UWERXWZDTULCPU-NFKLAVEJSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(CC1)CCC1(F)F)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(CC1)CCC1(F)F)=O UWERXWZDTULCPU-NFKLAVEJSA-N 0.000 description 1
- LBTVWJCPUQFTDU-NFKLAVEJSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCc1ccnc(F)c1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCc1ccnc(F)c1 LBTVWJCPUQFTDU-NFKLAVEJSA-N 0.000 description 1
- UMOIFYOLNHAAML-HVLWHFFDSA-N CC(C)CN[C@@](CCC1)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)C1[C@]1(C)C2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1 Chemical compound CC(C)CN[C@@](CCC1)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)C1[C@]1(C)C2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1 UMOIFYOLNHAAML-HVLWHFFDSA-N 0.000 description 1
- AMHSNZCPOYHRAQ-HOEBOJOYSA-N CC(C)[C@H](CC1)C([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)C2[C@]2(C)C4C(C)(C)C(c(cc4)ccc4C(OC)=O)=CC2)[C@]13N=C=O Chemical compound CC(C)[C@H](CC1)C([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)C2[C@]2(C)C4C(C)(C)C(c(cc4)ccc4C(OC)=O)=CC2)[C@]13N=C=O AMHSNZCPOYHRAQ-HOEBOJOYSA-N 0.000 description 1
- OKFBTZKRAUFMNK-VOTSOKGWSA-N CC/C(/F)=C\C(C)(C)OC Chemical compound CC/C(/F)=C\C(C)(C)OC OKFBTZKRAUFMNK-VOTSOKGWSA-N 0.000 description 1
- KUTPRXZITXHULJ-BAMHPCRESA-N CCC(C)(C)C(CC1)CC(CC2)[C@]1(C)[C@](C)(CC1)[C@H]2C(CCC2)[C@@]12N Chemical compound CCC(C)(C)C(CC1)CC(CC2)[C@]1(C)[C@](C)(CC1)[C@H]2C(CCC2)[C@@]12N KUTPRXZITXHULJ-BAMHPCRESA-N 0.000 description 1
- QZKZCEBFLZYBGQ-DOGNIXTISA-N CC[C@@H]1C(C)[C@@]2(C)[C@@H](C)[C@H](C)[C@@H](C)[C@H](C(C=C)C(OC)=O)C(C)(C)C2CC1 Chemical compound CC[C@@H]1C(C)[C@@]2(C)[C@@H](C)[C@H](C)[C@@H](C)[C@H](C(C=C)C(OC)=O)C(C)(C)C2CC1 QZKZCEBFLZYBGQ-DOGNIXTISA-N 0.000 description 1
- BIKULLBDZQBSQL-UHFFFAOYSA-N CN(c1c(CO2)ccc(Cl)c1)C2=O Chemical compound CN(c1c(CO2)ccc(Cl)c1)C2=O BIKULLBDZQBSQL-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- VIRSIQNRLMQTIL-JBOOICDFSA-N C[C@@H](CC(C(C)(C)C(c(cc1)ccc1C(OC)=O)=CC1)[C@@]1(C)C1CC2)C1[C@](C)(CC1)[C@H]2C(C(CC2)C(C)=C)[C@@]12NCCCl Chemical compound C[C@@H](CC(C(C)(C)C(c(cc1)ccc1C(OC)=O)=CC1)[C@@]1(C)C1CC2)C1[C@](C)(CC1)[C@H]2C(C(CC2)C(C)=C)[C@@]12NCCCl VIRSIQNRLMQTIL-JBOOICDFSA-N 0.000 description 1
- QUHVRXKSQHIZNV-UHFFFAOYSA-N FC1(CNC1)F Chemical compound FC1(CNC1)F QUHVRXKSQHIZNV-UHFFFAOYSA-N 0.000 description 1
- HHEKNWQXFVOUNJ-UHFFFAOYSA-N NCCN(CCC1)C1=O Chemical compound NCCN(CCC1)C1=O HHEKNWQXFVOUNJ-UHFFFAOYSA-N 0.000 description 1
- KWGFISNERABFPJ-UHFFFAOYSA-N O=S1(CCN(CCCl)CC1)=O Chemical compound O=S1(CCN(CCCl)CC1)=O KWGFISNERABFPJ-UHFFFAOYSA-N 0.000 description 1
- VAJSFWFPXNWBLF-UHFFFAOYSA-N OCCCN(CC1)CCS1(=O)=O Chemical compound OCCCN(CC1)CCS1(=O)=O VAJSFWFPXNWBLF-UHFFFAOYSA-N 0.000 description 1
- MPACUVIDHVFZBK-UHFFFAOYSA-N OCCNC(CC1)CS1(=O)=O Chemical compound OCCNC(CC1)CS1(=O)=O MPACUVIDHVFZBK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437893P | 2011-01-31 | 2011-01-31 | |
| US61/437,893 | 2011-01-31 | ||
| PCT/US2012/022852 WO2012106190A1 (en) | 2011-01-31 | 2012-01-27 | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503595A JP2014503595A (ja) | 2014-02-13 |
| JP2014503595A5 JP2014503595A5 (enExample) | 2015-02-26 |
| JP6001560B2 true JP6001560B2 (ja) | 2016-10-05 |
Family
ID=45567147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551362A Active JP6001560B2 (ja) | 2011-01-31 | 2012-01-27 | Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8846647B2 (enExample) |
| EP (1) | EP2670765B1 (enExample) |
| JP (1) | JP6001560B2 (enExample) |
| KR (1) | KR101886467B1 (enExample) |
| CN (1) | CN103429607B (enExample) |
| AR (1) | AR085053A1 (enExample) |
| AU (1) | AU2012212509B2 (enExample) |
| BR (1) | BR112013019419A2 (enExample) |
| CA (1) | CA2826113C (enExample) |
| CL (1) | CL2013002185A1 (enExample) |
| CO (1) | CO6751275A2 (enExample) |
| EA (1) | EA022470B1 (enExample) |
| ES (1) | ES2653847T3 (enExample) |
| IL (1) | IL227678B (enExample) |
| MA (1) | MA34909B1 (enExample) |
| MY (1) | MY162186A (enExample) |
| PE (1) | PE20141152A1 (enExample) |
| PH (1) | PH12013501528A1 (enExample) |
| PT (1) | PT2670765T (enExample) |
| SG (1) | SG192144A1 (enExample) |
| TN (1) | TN2013000321A1 (enExample) |
| TW (1) | TWI628188B (enExample) |
| UY (1) | UY33886A (enExample) |
| WO (1) | WO2012106190A1 (enExample) |
| ZA (1) | ZA201306546B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015510515A (ja) * | 2012-02-15 | 2015-04-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド |
| JP2015516422A (ja) * | 2012-05-07 | 2015-06-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20182060T1 (hr) | 2008-04-18 | 2019-03-22 | Reata Pharmaceuticals, Inc. | Antioksidantni modulatori upale: derivati oleanolne kiseline s amino i drugim modifikacijama na c-17 |
| TW201006474A (en) | 2008-04-18 | 2010-02-16 | Reata Pharmaceuticals Inc | Natural products including an anti-flammatory pharmacore and methods of use |
| BRPI0911208B1 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals, Inc | Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica |
| ES2613964T3 (es) | 2008-04-18 | 2017-05-29 | Reata Pharmaceuticals, Inc. | Moduladores de inflamación antioxidantes: Derivados de ácido oleanólico homologado C-17 |
| AR084353A1 (es) | 2010-12-17 | 2013-05-08 | Reata Pharmaceuticals Inc | Enonas triciclicas de pirazolilo y pirimidinilo utiles como agentes antiinflamatorios y/o antioxidantes y composiciones farmaceuticas que las contienen |
| HUE026371T2 (en) * | 2011-01-31 | 2016-05-30 | Bristol Myers Squibb Co | C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices |
| PT2683731T (pt) | 2011-03-11 | 2019-07-12 | Reata Pharmaceuticals Inc | Derivados de triterpenóides c4-monometil e os métodos de utilização dos mesmos |
| EA023463B1 (ru) | 2011-09-21 | 2016-06-30 | Бристол-Майерс Сквибб Компани | Производные бетулиновой кислоты с противовирусной активностью |
| UA116209C2 (uk) | 2012-04-27 | 2018-02-26 | Ріта Фармасьютікалз, Інк. | 2,2-дифторпропіонамідні похідні бардоксолон-метилу, їхні поліморфні форми і способи застосування |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| AU2013304102B2 (en) * | 2012-08-15 | 2016-09-01 | Glaxo Group Limited | Chemical process |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| EA029174B1 (ru) | 2012-09-10 | 2018-02-28 | Рита Фармасьютикалз, Инк. | C17-алкандиильные и алкендиильные производные олеаноловой кислоты и способы их применения |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| BR112015018491A2 (pt) * | 2013-02-06 | 2017-07-18 | Bristol Myers Squibb Co | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv |
| EA027861B1 (ru) | 2013-02-25 | 2017-09-29 | Бристол-Майерс Сквибб Компани | C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе |
| UA120927C2 (uk) | 2014-04-11 | 2020-03-10 | Віів Гелскер Юк (Но.4) Лімітед | Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл |
| US9920090B2 (en) | 2014-06-19 | 2018-03-20 | VIIV Healthcare UK (No.5) Limited | Betulinic acid derivatives with HIV maturation inhibitory activity |
| US10047118B2 (en) | 2014-11-14 | 2018-08-14 | VIIV Healthcare UK (No.5) Limited | C17-aryl substituted betulinic acid analogs |
| RU2017118489A (ru) | 2014-11-14 | 2018-12-14 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Оксолупеновые производные |
| CN107428798A (zh) * | 2015-04-14 | 2017-12-01 | Viiv保健英国第四有限公司 | 生产hiv成熟抑制剂的方法 |
| KR20180028535A (ko) | 2015-07-28 | 2018-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체 |
| JP2018521093A (ja) | 2015-07-28 | 2018-08-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｈｉｖ感染を予防または治療するためのベツイン誘導体 |
| WO2017025901A1 (en) * | 2015-08-11 | 2017-02-16 | Hetero Research Foundation | Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors |
| EP3353190B1 (en) | 2015-09-23 | 2021-03-17 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
| KR20180054826A (ko) | 2015-09-24 | 2018-05-24 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 성숙 억제 활성을 갖는 화합물 |
| BR112018010163A2 (pt) | 2015-11-20 | 2018-11-21 | Viiv Healthcare Uk No 4 Ltd | formulação, e, método para tratamento de infecção por hiv |
| AU2017208874A1 (en) * | 2016-01-20 | 2018-08-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Amine derivatives of lupanes with HIV maturation inhibitory activity |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| WO2018002849A1 (en) * | 2016-06-30 | 2018-01-04 | VIIV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| WO2018044822A1 (en) * | 2016-08-31 | 2018-03-08 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
| BR112020002322A2 (pt) | 2017-08-04 | 2020-09-01 | Ardelyx, Inc. | derivados de ácido glicirretinínico para o tratamento de hipercalemia |
| JP6926939B2 (ja) * | 2017-10-23 | 2021-08-25 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
| JP6977474B2 (ja) * | 2017-10-23 | 2021-12-08 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
| US20210347813A1 (en) | 2018-04-24 | 2021-11-11 | Viiv Healthcare Uk (No. 5) Limited | Compounds with hiv maturation inhibitory activity |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| US11858959B2 (en) | 2019-02-07 | 2024-01-02 | Ardelyx, Inc. | Glycyrrhetinic acid derivatives for use in treating hyperkalemia |
| MY201070A (en) | 2019-02-11 | 2024-02-01 | Hetero Labs Ltd | Novel triterpene derivatives as hiv inhibitors |
| WO2021016191A1 (en) | 2019-07-19 | 2021-01-28 | Reata Pharmaceuticals, Inc. | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof |
| GB2598300A (en) * | 2020-08-21 | 2022-03-02 | Univ Durham | Cross-linking method and applications in bioconjugation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| JP2007529544A (ja) | 2004-03-17 | 2007-10-25 | パナコス ファーマシューティカルズ， インコーポレイテッド | ３−ｏ−（３’，３’−ジメチルスクシニル）ベツリン酸の製薬的な塩 |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US8067620B2 (en) | 2005-05-04 | 2011-11-29 | Medicines For Malaria Venture Mmv | Dispiro 1,2,4-trioxolane antimalarials |
| WO2008127364A2 (en) * | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| EP2257567A1 (en) * | 2008-02-14 | 2010-12-08 | Virochem Pharma Inc. | Novel 17 beta lupane derivatives |
| US9067966B2 (en) * | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| EP2576585B8 (en) * | 2010-06-04 | 2016-12-21 | VIIV Healthcare UK (No.5) Limited | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| WO2011153319A1 (en) * | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
-
2012
- 2012-01-27 EP EP12702947.8A patent/EP2670765B1/en active Active
- 2012-01-27 JP JP2013551362A patent/JP6001560B2/ja active Active
- 2012-01-27 US US13/359,727 patent/US8846647B2/en active Active
- 2012-01-27 SG SG2013056858A patent/SG192144A1/en unknown
- 2012-01-27 MA MA36183A patent/MA34909B1/fr unknown
- 2012-01-27 PH PH1/2013/501528A patent/PH12013501528A1/en unknown
- 2012-01-27 MY MYPI2013701325A patent/MY162186A/en unknown
- 2012-01-27 CA CA2826113A patent/CA2826113C/en active Active
- 2012-01-27 ES ES12702947.8T patent/ES2653847T3/es active Active
- 2012-01-27 WO PCT/US2012/022852 patent/WO2012106190A1/en not_active Ceased
- 2012-01-27 AU AU2012212509A patent/AU2012212509B2/en active Active
- 2012-01-27 CN CN201280014966.XA patent/CN103429607B/zh active Active
- 2012-01-27 PE PE2013001719A patent/PE20141152A1/es active IP Right Grant
- 2012-01-27 KR KR1020137023070A patent/KR101886467B1/ko active Active
- 2012-01-27 EA EA201391127A patent/EA022470B1/ru not_active IP Right Cessation
- 2012-01-27 BR BR112013019419A patent/BR112013019419A2/pt not_active Application Discontinuation
- 2012-01-27 PT PT127029478T patent/PT2670765T/pt unknown
- 2012-01-31 UY UY0001033886A patent/UY33886A/es not_active Application Discontinuation
- 2012-01-31 AR ARP120100314A patent/AR085053A1/es unknown
- 2012-01-31 TW TW101103140A patent/TWI628188B/zh active
-
2013
- 2013-07-26 TN TNP2013000321A patent/TN2013000321A1/fr unknown
- 2013-07-28 IL IL227678A patent/IL227678B/en active IP Right Grant
- 2013-07-30 CL CL2013002185A patent/CL2013002185A1/es unknown
- 2013-08-27 CO CO13203030A patent/CO6751275A2/es unknown
- 2013-08-30 ZA ZA2013/06546A patent/ZA201306546B/en unknown
-
2014
- 2014-07-24 US US14/339,572 patent/US20140343000A1/en not_active Abandoned
-
2016
- 2016-02-04 US US15/015,741 patent/US20160151387A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015510515A (ja) * | 2012-02-15 | 2015-04-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド |
| JP2015516422A (ja) * | 2012-05-07 | 2015-06-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6001560B2 (ja) | Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド | |
| JP6000283B2 (ja) | Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン | |
| JP6155285B2 (ja) | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド | |
| ES2548905T3 (es) | Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH | |
| JP6212545B2 (ja) | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド | |
| JP6186010B2 (ja) | Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 | |
| CA2944778C (en) | Triterpenoids with hiv maturation inhibitory activity | |
| ES2957767T3 (es) | Triterpenoides modificados en C-3 y C-17 como inhibidores del VIH-1 | |
| NZ614871B2 (en) | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160105 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160325 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160901 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6001560 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |